New Dual-Action antibody shows promise for tough lymphoma cases
NCT ID NCT05189093
First seen Nov 01, 2025 · Last updated Jun 19, 2026 · Updated 32 times
Summary
This study tested an experimental drug called HX009 in 48 adults with lymphoma that returned or didn't respond to standard treatments. HX009 is a special antibody designed to attack cancer cells from two angles (CD47 and PD-1) to boost the immune system's fight. The main goal was to see how many patients' tumors shrank or disappeared, and the study has already been completed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cancer Hospital Chinese Academy of Medical Sciense
Beijing, Beijing Municipality, China
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.